Management of Stage 4 Breast Carcinoma

Initial Assessment and Staging

A comprehensive staging workup is essential and should include history, physical examination, laboratory tests, and imaging of chest, abdomen, and bone, as recommended by the European Society for Medical Oncology 2, 3
PET-CT may be used instead of CT scans and bone scan if available, according to the European Society for Medical Oncology 4
Brain imaging is not routinely recommended in asymptomatic patients, including those with HER2-positive or triple-negative disease, as stated by the European Society for Medical Oncology 2
Biopsy of a metastatic lesion should be performed if easily accessible to confirm diagnosis and reassess biological markers, such as HR and HER2 status, as recommended by the European Society for Medical Oncology 2, 3

The primary goals of treatment for stage 4 breast cancer are palliating symptoms, prolonging survival, and maintaining or improving quality of life, according to the National Comprehensive Cancer Network 1
Treatment decisions should consider multiple factors, including previous therapies and their toxicities, tumor burden, and patient preferences, as recommended by the European Society for Medical Oncology 3

Endocrine therapy is the preferred first-line treatment for HR-positive disease, unless there is concern for endocrine resistance or need for rapid response, as stated by the European Society for Medical Oncology 3
Chemotherapy is the mainstay of treatment for triple-negative breast cancer, according to the National Comprehensive Cancer Network and the European Society for Medical Oncology 1, 3
Sequential single-agent chemotherapy is generally preferred over combination chemotherapy, unless there is need for rapid symptom control or management of life-threatening visceral metastases, as recommended by the European Society for Medical Oncology 3

For patients not previously exposed to anthracyclines or taxanes, these agents are usually considered first-line options, as recommended by the European Society for Medical Oncology 3
For patients previously treated with anthracyclines and taxanes, options include capecitabine, vinorelbine, or eribulin, according to the European Society for Medical Oncology 3
Sequential monotherapy is generally preferred over combination chemotherapy to minimize toxicity while maintaining efficacy, as stated by the European Society for Medical Oncology 5

The primary approach for metastatic breast cancer is systemic therapy, not surgery, according to the National Comprehensive Cancer Network and the European Society for Medical Oncology 1, 4
Surgery may be considered in select patients for palliation of symptoms or when complete local clearance can be achieved, as recommended by the National Comprehensive Cancer Network 1

A small subset of patients with oligometastatic disease or highly chemosensitive disease may achieve complete remission with a multimodal approach, including local-regional treatments, as stated by the European Society for Medical Oncology 3, 5
Early introduction of expert palliative care, including effective pain control, should be a priority, according to the European Society for Medical Oncology 6
Treatment should be tailored to the individual patient based on disease characteristics, previous treatments, and patient preferences, as recommended by the European Society for Medical Oncology 3

Evaluation of response to therapy should occur every 2-4 months for endocrine therapy and after 2-4 cycles for chemotherapy, as recommended by the European Society for Medical Oncology 4
Tumor markers may aid in evaluating response, particularly in patients with non-measurable disease, according to the European Society for Medical Oncology 2

Do not withhold effective therapy based solely on patient age, as stated by the European Society for Medical Oncology 3
Do not rely on tumor markers alone to initiate a change in treatment, according to the European Society for Medical Oncology 2
Avoid unnecessary surgery for the primary tumor when systemic disease control is the priority, as recommended by the National Comprehensive Cancer Network and the European Society for Medical Oncology 1, 4